Previous 10 | Next 10 |
Investors bailed out of tech and growth stocks even as tech insiders added more. Insider buying on the XLK ETF has surged to the highest in the last ten years. We discuss why the bottoming in tech and growth stocks could be forming. Subsequently, we believe the outperformance in growt...
The release of Shockwave C² is a similar event to TAVRs for Edwards Lifesciences. Considering the cardiovascular industry tailwinds, the unique niche in calcified stenosis, and safety profile should allow a similar growth trajectory for SWAV. A tremendous earnings report...
Fisher's 13F portfolio value decreased from ~$179B to ~$165B in Q1 2022. Nvidia, Intuit, Broadcom, Verizon, Uber, AMD, & Meta Platforms were increased while reducing Intel, Walmart, Walt Disney, Cisco, UnitedHealth, Starbucks & Visa this quarter. The top three positions ar...
IYH gained 12% during 7 weeks from February 22, and then fell by 9% in the next 3 weeks. IYH posted strong price returns over the medium and long term, but generated 1% yield. Biotechnology and Life Sciences Tools & Services companies historically had cyclical price movements,...
Image source: The Motley Fool. Edwards Lifesciences (NYSE: EW) Q1 2022 Earnings Call Apr 26, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Edwards Lifesciences (EW) Q1 2022 Earnings Call Transcript
Edwards Lifesciences Corporation (EW) Q1 2022 Earnings Conference Call April 26, 2022 05:00 PM ET Company Participants Mark Wilterding - Vice President, Investor Relations & Treasurer Mike Mussallem - Chairman & Chief Executive Officer Scott Ullem - Chief Financial Officer Conference ...
Shares of Edward Lifesciences' (NYSE:EW) are down 4% in after-hours trading even though its Q1 2022 net income increased ~10% year over year. In addition, the the heart-focused medical device maker beat on the top and bottom lines. Net income in the quarter rose to $373.6M ($0.39 diluted earn...
Edwards Lifesciences press release (NYSE:EW): Q1 Non-GAAP EPS of $0.60 beats by $0.03. Revenue of $1.34B (+9.8% Y/Y) beats by $30M. Q1 TAVR sales grew 11 percent; underlying 14 percent Overall, the company is reaffirming sales guidance for all product groups. Full year 2022 sales are ex...
EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS PR Newswire IRVINE, Calif. , April 26, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2022. First Quarter Hi...
Edwards Lifesciences (NYSE:EW) is scheduled to announce Q1 earnings results on Tuesday, April 26th, after market close. The consensus EPS Estimate is $0.57 (+5.6% Y/Y) and the consensus Revenue Estimate is $1.31B (+7.4% Y/Y). Over the last 2 years, EW has beaten EPS estimates 63% of the time ...
News, Short Squeeze, Breakout and More Instantly...
Edwards Lifesciences Corporation Company Name:
EW Stock Symbol:
NYSE Market:
Edwards Lifesciences Corporation Website:
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2024) - East West Petroleum Corp. (TSXV: EW) ("East West" or the "Company") is pleased to provide this update in regard to the status of the proposed return of capital announced on June 19, 2024 . The Company has prepared and mailed its ...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
2024-07-25 16:00:08 ET Pito Chickering from Deutsche Bank issued a price target of $85.00 for EW on 2024-07-25 13:36:00. The adjusted price target was set to $85.00. At the time of the announcement, EW was trading at $60.58. The overall price target consensus is at $109....